Loading clinical trials...
Loading clinical trials...
Nucleoside Analogue in Late Preganancy to Prevent Vertical Transmission of Hepatitis B Virus
To explore the antiviral effect of nucleoside analogue in late pregnancy and the safety of the antiviral drug to fetus.To establish the best therapy strategy to pregnant women with high level of HBV DNA.
Telbivudine and Lamivudine,a preganancy category B medication,reduces HBV DNA and normalizes serum ALT in chronic hepatitis B patients with few adverse effects.Two aspects on the drug use in pregnancy will be evaluated prospectively in this study.
Age
20 - 35 years
Sex
FEMALE
Healthy Volunteers
No
Start Date
March 1, 2009
Primary Completion Date
July 1, 2012
Completion Date
July 1, 2013
Last Updated
July 30, 2013
700
ACTUAL participants
Telbivudine
DRUG
Lamivudine
DRUG
Lead Sponsor
Hua Zhang
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06868264